The Telomere Length Signature in Leukemias—From Molecular Mechanisms Underlying Telomere Shortening to Immunotherapeutic Options Against Telomerase
Stella Baliou(National Hellenic Research Foundation), Eftichia Stiakaki(University Hospital of Heraklion), Miruna-Maria Apetroaei(Carol Davila University of Medicine and Pharmacy), Elena Vakonaki(University of Crete), Andreea Letiția Arsene(Carol Davila University of Medicine and Pharmacy), Aristidis Tsatsakis(University of Crete), Πέτρος Ιωάννου(University of Crete), Iordanis Pelagiadis(University of Crete), Eleftheria Hatzidaki(University of Crete), Manolis Tzatzarakis(University of Crete)
Cited by 4
Related Papers
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
|International Journal of Oncology|2015|363
Mechanistic understanding of nanoparticles’ interactions with extracellular matrix: the cell and immune system
|Particle and Fibre Toxicology|2017|248
Dermal & inhalation exposure of operators during fungicide application in vineyards. Evaluation of coverall performance
|The Science of The Total Environment|2013|56
Role of telomere length in human carcinogenesis (Review)
|International Journal of Oncology|2023|55
Post-translational modifications in MeHg-induced neurotoxicity
|Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease|2018|48